This year, voters are clear about the health care challenges they’re experiencing and the solutions they want to see. More on our blog: phrma.org/Blog/ICYMI-Vot…

Explainer: Why are US pharmacy benefit managers under fire? reut.rs/49ED8gp

“Plans are charging more and they’re covering less, so it’s a double whammy,” notes a co-author of a new USC Schaeffer Center study. Insurers & PBMs are reducing access to medicines, often leaving Medicare Part D beneficiaries with fewer treatment options. bit.ly/3U3YL45

The Biden Administration's proposal to abuse march in rights could have disastrous ramifications well beyond the biopharmaceutical industry, warns Steve Forbes — it could lay the ground for 'political cronyism' & reduce investment incentives across green energy, tech & others.

Experts have warned the proposed Medicaid 'stacking policy':

1. Risks disrupting a program with a long-standing history of success
2. Does nothing to solve the opaque system of PBM fees
3. Would be impossible to implement

More in Newsweek Opinion:

A startling 63% of Medicare Part B patients with 5 serious complex conditions — nearly 117,000 people — could lose access to their treatment if the government were to adopt ICER’s value assessments as the basis for Medicare Part B coverage decisions. phrma.org/Blog/New-analy…

Dolores' story in Daily Republic News is an example of life-changing medicine — in her case, a cure for Hepatitis C. But, as she says, 'medicines also need to be affordable,' and PBMs often get in the way of that. Here's what policymakers can do to help: dailyrepublic.com/opinion/commen…

A new activist-funded study published in JAMA Network is fueling misleading rhetoric around the cost of diabetes and anti-obesity medicines. Here are 5 things the study gets wrong: phrma.org/blog/what-rece…

Addressing the significant burden of Alzheimer's disease is a bipartisan issue. Here, POLITICO and Eisai US outline the policy solutions that can support treatment access, improve diagnostic times and foster better public/private collaboration.
politico.com/sponsored/2024…

Yesterday's White House event was another missed opportunity to address the real barriers between patients and their medicines. When companies have introduced lower-priced versions of their medicines, insurers and PBMs have refused to cover them because they make less money.

Continued U.S. leadership in the development of safe and effective #vaccines is essential to protecting lives – both at home and around the globe. As the World Vaccine Congress convenes, here's what you need to know: bit.ly/3xfAPD4 World Vaccine Congress

An important callout from this report: Nine of the top 10 hospitals participate in the 340B program – which is supposed to help low-income patients access medicines, not pad the bottom lines of big hospitals. More evidence why we must #Fix340B :

Nearly half of the Fortune 25 companies, like PBMs, generate revenue from a program meant to help low-income patients. #340B was not meant to line the pockets of wealthy companies. Learn more: phrma.org/Blog/PBMs-usin…

In 47 states and DC, more than half of DSH hospitals (hospitals that disproportionately serve low-income patients) earn more in #340B profit than they spend on charity care. This report adds to a long list showing the 340B program urgently needs to be fixed.

More transparency on the PBM industry is important, but not enough. Even as the FTC, state AGs, federal and state lawmakers look under the hood of the broken PBM model, the big #PBMs are finding new ways to drive out competition and drive up costs.

This Friday, March 29, join GSK US and other leaders in health care for a STAT discussion about how we can ensure the patient voice is included in conversations about the significant medical breakthroughs of today. Register for the virtual event: statnews.com/event/champion…

Caregivers are unsung heroes in patient care, facing demanding tasks comparable to a full-time job. Take a look at how recent treatment advances are offering hope to both patients and caregivers alike. phrma.org/Blog/The-Impac…

When it comes to patient-centered policy, legislators are missing the mark. Tomorrow, join Elizabeth Carpenter and Voters for Cures’ Terry Uhl at Reuters’ Pharma USA to hear about biopharmaceutical R&D’s role in improving patient lives #REpharmaUSA : events.reutersevents.com/pharma/pharma-…

Some of the most promising clinical research for medicines happens after a medicine is first FDA approved. A new study in Journal of Medical Economics adds to the body of evidence that the IRA’s price setting provisions threaten this post-approval R&D. phrma.org/Blog/ICYMI-Mor…

'Unless the administration withdraws its proposal, the United States will return to the days when the most promising federally backed discoveries never left university labs.' technologyreview.com/2024/03/08/108…